Form 4: Beam Therapeutics Director Receives Stock Option Grant

Director John Maraganore was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard compensation.

Summary

• Director John Maraganore received a grant of 19,676 stock options on June 3, 2026.
• The options have an exercise price of $29.55 per share.
• The options are set to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $29.55 exercise price.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level scientific and industry expertise.

Comparison to Industry Standards

• The vesting schedule of one year or the next annual meeting is consistent with standard corporate governance practices for board members in mid-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 3, 2027, or the date of the 2027 annual meeting.

Key Dates

Keywords

Beam Therapeutics, BEAM, Director Compensation, Stock Options, Insider Transaction, Biotech